Ep 279 Why is Rick Rubin Selling Athletic Nicotine? Kitty Wants to Know

Ep 279 Why is Rick Rubin Selling Athletic Nicotine? Kitty wants to know. Why is nicotine suddenly being marketed as a wellness product? In this episode, Kitty O’Compost turns her satirical eye toward the rise of “athletic nicotine,” a new generation of premium nicotine pouches aimed at runners, creatives, executives, and health-conscious high performers. Using Rick Rubin’s podcast sponsorship as a starting point, Kitty explores how a highly addictive substance is being wrapped in the language of mindfulness, optimization, and intentional living. With humor, skepticism, and a trip through the False Consensus Detector, Kitty examines the growing effort to separate nicotine from its tobacco past and position it alongside coffee, supplements, and other performance tools. Along the way, she asks whether beautiful branding can obscure biological reality and whether a wellness halo can transform public perception without changing the underlying molecule. Avis closes the episode with a personal reflection on his admiration for Rick Rubin’s work and his repeated requests that Rubin reconsider promoting athletic nicotine to his audience. Listen for the peace. Referenced Materials & Studies: Corporate Strategy: Magazine, "How This Founder Changed Minds Instead of Pushing Sales" by Christopher Cason (April 2026). Link to Inc. Article Cardiovascular Risks:The American Heart Association (AHA) Policy Statement, "Impact of Smokeless Oral Nicotine Products on Cardiovascular Disease: Implications for Policy, Prevention, and Treatment" (Published in Circulation). This study tracks the adverse effects of oral pouches on cardiovascular biomarkers and the specific dangers of synthetic nicotine. https://pubmed.ncbi.nlm.nih.gov/39624904/ Excerpt: “Abstract. Smokeless oral nicotine products are addictive, and their use has potential adverse effects on some but not all biomarkers of cardiovascular risk. The use of some types of these products, for instance, is associated with an increased mortality risk in those with ischemic heart or cerebrovascular disease. Similarly, smokeless tobacco has the potential to increase the risk of oral cancer, but the risks depend on the chemical composition of the product. The market of smokeless oral nicotine products has transformed since the last American Heart Association smokeless tobacco policy statement. Several varieties of tobacco-free oral nicotine products-including oral nicotine pouches; nontherapeutic nicotine gums, lozenges, and tablets; and nicotine gummies-have rapidly proliferated. The sales of oral nicotine pouches, in particular, have increased substantially; however, no data are available on their cardiovascular or health risks. In addition, synthetic (compared with tobacco-derived) nicotine has been used in some brands of oral nicotine products, but its cardiovascular and health effects have been inadequately studied. Robust public policy levers are identified to support ending addiction to all commercial tobacco products. Critical components and policy initiatives include clinicians emphasizing the prevention of tobacco product initiation and supporting cessation with established pharmacological and behavioral tobacco dependence treatment therapies as primary goals for achieving an end to commercial tobacco and nicotine addiction.” Public Health Data:The Centers for Disease Control and Prevention (CDC) Fact Sheet on Oral Nicotine Pouches, highlighting rapid dependency loops, systemic toxicity, and the acceleration of youth addiction through modern marketing. Excerpts: “There are no safe tobacco products, including nicotine pouches. This is especially true for youth, young adults, and women who are pregnant.” “More research is needed to better understand the short- and long-term health effects of using nicotine pouches.” Join the Community / Get the Books:AvisKalfsbeek.com